Annual Uterine Cancer Biology Symposium

年度子宫癌生物学研讨会

• 批准号: 8007267
• 负责人: RUSSELL R BROADDUS
• 金额: $ 1万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8007267
• 关键词: American Cancer Society; Atypical hyperplasia; Basic Science; Biological Markers; Biological Models; Biology; Cancer Biology; Cessation of life; Clinical; Clinical Investigator; Clinical Management; Clinical Trials; Collaborations; Communities; Complex; Consensus; Country; Development; Employee Strikes; Endocrinology; Endometrial Carcinoma; Faculty; Gynecologic; Hereditary Nonpolyposis Colorectal Neoplasms; Incidence; Institution; Investments; Laboratory Scientists; Lesion; Malignant Neoplasms; Molecular; New York; Obesity; Participant; Patients; Postdoctoral Fellow; Prevention; Research; Rosa; Scientist; Series; Site; Syndrome; Translational Research; Translations; United States; Universities; Uterine Cancer; Washington; Woman; anticancer research; cohort; endometrial cancer prevention; high risk; innovation; malignant breast neoplasm; meetings; mortality; prevent; professor; public health relevance; symposium; tumor

DESCRIPTION (provided by applicant): Endometrial cancer is the most common gynecologic malignancy in the United States and the fourth most common cancer in women with an estimated 42,160 cases and 7,780 deaths in 2009. According to the American Cancer Society, incidence of endometrial cancer rose 12% and mortality rose 23% in the last decade. Several features of endometrial cancer make it a highly preventable cancer. One, many endometrial cancers are associated with the precursor lesion complex atypical hyperplasia. Second, there are well established high risk cohorts, including obese women and women with Lynch syndrome (or Hereditary Non- polyposis Colorectal Cancer syndrome). Clinical, translational, and basic research efforts toward uterine cancer have traditionally lagged behind research in other sites. This limitation can be attributed to the absence of an organized scientific and patient focus on these tumors. This lack of substantive investment in uterine cancer research is striking when compared to other tumor sites. For innovative, translational research in endometrial cancer prevention to move forward, it is necessary to have a consistent forum to bring together clinical investigators and laboratory scientists from a variety of different institutions across the country. Therefore, we propose to continue our efforts to bring the endometrial cancer community together with the Annual Uterine Cancer Biology Symposium, which aims to: 1) provide a meaningful forum to discuss cutting- edge developments in endometrial cancer biology; 2) attract experts in related fields (such as breast cancer, endocrinology, cancer biology) to encourage multi-disciplinary interactions; 3) promote collaborations between basic scientists and clinical investigators for the development of more innovative, high-impact translational research in endometrial cancer; and 4) encourage young, talented post-doctoral fellows, clinical residents/fellows, and faculty at the assistant professor level to enter the field of endometrial cancer research. For each symposium, a mixture of clinical topics and basic science topics are presented to promote the development of quality translational research in prevention. We have successfully brought together speakers and participants from across the United States for 6 meetings since 2002. These have been held at M. D. Anderson in Houston, TX, Washington University in St. Louis, MO, and Memorial Sloan-Kettering in New York, NY. Topics for the annual symposium series have included basic biology and translational opportunities in prevention and treatment, translational research and clinical management of uterine cancers, strategies in the management of advanced uterine cancer, a consensus conference on endometrial cancer and Lynch syndrome (HNPCC), integrating molecular biomarkers into clinical trials, and obesity and endometrial cancer. The 7th annual symposium will take place in the winter of 2010 and proposes to explore the translation of discoveries in model systems to advance the treatment and prevention of endometrial cancer. PUBLIC HEALTH RELEVANCE: Endometrial cancer is the most common gynecologic malignancy in the United States and the fourth most common cancer in women. Clinical, translational, and basic research efforts toward preventing uterine cancer have traditionally lagged behind research in other sites. In order to provide a multi-disciplinary and multi- institutional forum to advance the understanding of endometrial cancer, we propose to continue our efforts to hold an Annual Uterine Cancer Biology Symposium.

描述（由申请人提供）：子宫内膜癌是美国最常见的妇科恶性肿瘤，也是女性中第四常见的癌症，2009年估计有42，160例病例和7，780例死亡。根据美国癌症协会的数据，在过去十年中，子宫内膜癌的发病率上升了12%，死亡率上升了23%。子宫内膜癌的几个特征使其成为高度可预防的癌症。许多子宫内膜癌的前病变伴有复杂的不典型增生。第二，存在完善的高风险群组，包括肥胖女性和患有Lynch综合征（或遗传性非息肉病性结直肠癌综合征）的女性。子宫癌的临床、转化和基础研究工作传统上落后于其他地区的研究。这种局限性可以归因于缺乏有组织的科学和患者对这些肿瘤的关注。与其他肿瘤部位相比，子宫癌研究缺乏实质性投资是惊人的。为了推进子宫内膜癌预防的创新性转化研究，有必要建立一个一致的论坛，将来自全国各地不同机构的临床研究人员和实验室科学家聚集在一起。因此，我们建议继续努力，通过年度子宫癌生物学研讨会将子宫内膜癌社区聚集在一起，其目的是：1）提供一个有意义的论坛，讨论子宫内膜癌生物学的前沿发展; 2）吸引相关领域的专家（如乳腺癌、内分泌学、癌症生物学），鼓励多学科互动; 3）促进基础科学家和临床研究者之间的合作，以发展更具创新性的、高影响力的子宫内膜癌转化研究;和4）鼓励年轻，有才华的博士后研究员，临床住院医师/研究员，和助理教授级的教员进入子宫内膜癌研究领域。对于每个研讨会，提出了临床主题和基础科学主题的混合物，以促进高质量的预防转化研究的发展。 自2002年以来，我们成功地将来自美国各地的演讲者和参与者聚集在一起，举行了6次会议。这是在M。D.德克萨斯州休斯顿的安德森、密苏里州圣路易斯的华盛顿大学和纽约州纽约的斯隆-凯特琳纪念馆。年度研讨会系列的主题包括基础生物学和预防和治疗的转化机会，子宫癌的转化研究和临床管理，晚期子宫癌管理策略，子宫内膜癌和Lynch综合征（HNPCC）共识会议，将分子生物标志物纳入临床试验，肥胖和子宫内膜癌。第七届年度研讨会将于2010年冬季举行，并建议探索模型系统中发现的转化，以促进子宫内膜癌的治疗和预防。 公共卫生相关性：子宫内膜癌是美国最常见的妇科恶性肿瘤，也是女性第四常见的癌症。预防子宫癌的临床、转化和基础研究工作传统上落后于其他领域的研究。为了提供一个多学科和多机构的论坛，以促进对子宫内膜癌的理解，我们建议继续努力举办年度子宫癌生物学研讨会。